中度与轻度治疗性低温对院外心脏骤停昏迷幸存者死亡率和神经结局的影响:CAPITAL CHILL随机临床试验
该单中心、双盲、随机、优效性试验纳入389例院外心脏骤停昏迷幸存者,比较目标体温31°C与34°C治疗24小时对180天全因死亡或不良神经结局的影响。
要点
- 研究可能把握度不足,无法排除临床重要差异。
核心结论
- 在院外心脏骤停昏迷幸存者中,与目标温度34°C相比,目标温度31°C未显著降低180天死亡或不良神经结局发生率。
- 研究可能把握度不足,无法检测临床重要差异。
研究设计与样本
- 单中心、双盲、随机、临床优效性试验,在加拿大东安大略省三级心脏护理中心开展。
- 2013年8月4日至2020年3月20日共纳入389例院外心脏骤停患者,最终随访至2020年10月15日。
- 患者随机接受目标体温31°C(n=193)或34°C(n=196)治疗24小时。
- 主要分析纳入367例(平均年龄61岁;女性69例[19%]),366例(99.7%)完成试验。
主要发现
- 不良事件:31°C组 vs 34°C组深静脉血栓发生率为11.4% vs 10.9%,下腔静脉血栓发生率为3.8% vs 7.7%。
关键数值与推荐
- 不良神经结局定义为Disability Rating Scale评分大于5(范围0-29,29为最差结局[植物状态])。
临床怎么用
- 对于院外心脏骤停昏迷幸存者,目标温度31°C较34°C未显示额外获益,且ICU住院时间更长,不支持常规采用31°C。
局限性
- 研究可能把握度不足,无法检测临床重要差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Comatose survivors of out-of-hospital cardiac arrest experience high rates of death and severe neurologic injury. Current guidelines recommend targeted temperature management at 32 °C to 36 °C for 24 hours. However, small studies suggest a potential benefit of targeting lower body temperatures. OBJECTIVE: To determine whether moderate hypothermia (31 °C), compared with mild hypothermia (34 °C), improves clinical outcomes in comatose survivors of out-of-hospital cardiac arrest. DESIGN, SETTING, AND PARTICIPANTS: Single-center, double-blind, randomized, clinical superiority trial carried out in a tertiary cardiac care center in eastern Ontario, Canada. A total of 389 patients with out-of-hospital cardiac arrest were enrolled between August 4, 2013, and March 20, 2020, with final follow-up on October 15, 2020. INTERVENTIONS: Patients were randomly assigned to temperature management with a target body temperature of 31 °C (n = 193) or 34 °C (n = 196) for a period of 24 hours. MAIN OUTCOMES AND MEASURES: The primary outcome was all-cause mortality or poor neurologic outcome at 180 days. Neurologic outcome was assessed using the Disability Rating Scale, with poor neurologic outcome defined as a score greater than 5 (range, 0-29, with 29 being the worst outcome [vegetative state]). There were 19 secondary outcomes, including mortality at 180 days and length of stay in the intensive care unit. RESULTS: Among 367 patients included in the primary analysis (mean age, 61 years; 69 women [19%]), 366 (99.7%) completed the trial. The primary outcome occurred in 89 of 184 patients (48.4%) in the 31 °C group and in 83 of 183 patients (45.4%) in the 34 °C group (risk difference, 3.0% [95% CI, 7.2%-13.2%]; relative risk, 1.07 [95% CI, 0.86-1.33]; P = .56). Of the 19 secondary outcomes, 18 were not statistically significant. Mortality at 180 days was 43.5% and 41.0% in patients treated with a target temperature of 31 °C and 34 °C, respectively (P = .63). The median length of stay in the intensive care unit was longer in the 31 °C group (10 vs 7 days; P = .004). Among adverse events in the 31 °C group vs the 34 °C group, deep vein thrombosis occurred in 11.4% vs 10.9% and thrombus in the inferior vena cava occurred in 3.8% and 7.7%, respectively. CONCLUSIONS AND RELEVANCE: In comatose survivors of out-of-hospital cardiac arrest, a target temperature of 31 °C did not significantly reduce the rate of death or poor neurologic outcome at 180 days compared with a target temperature of 34 °C. However, the study may have been underpowered to detect a clinically important difference. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02011568.
引用
- Le May M, Osborne C, Russo J, et al. Effect of Moderate vs Mild Therapeutic Hypothermia on Mortality and Neurologic Outcomes in Comatose Survivors of Out-of-Hospital Cardiac Arrest: The CAPITAL CHILL Randomized Clinical Trial. JAMA. 2021. PMID: 34665203. doi:10.1001/jama.2021.15703
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。